Biochemistry, LDL Cholesterol

Article Author:
Yasaman Pirahanchi
Article Editor:
Martin Huecker
1/13/2019 11:08:52 PM
PubMed Link:
Biochemistry, LDL Cholesterol


LDL cholesterol, or low-density lipoprotein cholesterol, is a fat that circulates in the blood, moving cholesterol around the body to where it is needed for cell repair and depositing it inside of artery walls. Because cholesterol and triglycerides are insoluble in water, they must be associated with proteins to flow through the hydrophilic blood. [1]


The LDL particle is made of a monolayer of phospholipid, unesterified cholesterol forms the surface membrane, and fatty acid esters of cholesterol make up the hydrophobic core. One copy of the hydrophobic apo-B protein is embedded in the membrane, mediating the binding of LDL particles to specific cell-surface receptors. [2]

Issues of Concern

LDL receptor function is needed for uptake of LDL from the blood into hepatocytes.

Defects in LDL receptor function can cause hypercholesterolemia, known as familial hypercholesterolemia, an autosomal dominant disorder. Because LDL receptors on the surface of hepatocytes are necessary for the binding and subsequent uptake of LDL molecules in the blood, a genetic decrease in LDL receptor number would cause a decreased ability of hepatocytes to absorb LDL and would increase LDL in the blood. If this mutation is heterozygous, some LDL receptor will be present on the hepatocytes thus LDL is usually around 300 mg/dL. However, a homozygous mutation will result in the complete absence of LDL receptors on hepatocytes, increasing the LDL cholesterol levels up to 1000 mg/dL. [3]


The liver produces Very low-density lipoprotein (VLDL), which is metabolized to IDL by lipoprotein lipase (LPL). IDL is then converted to LDL by hepatic triglyceride lipase (HTGL). LDL and a portion of IDL particles are cleared from the circulation via the LDL receptors (LDL-Rc) expressed in the liver and other cells. [4]

The LDL receptor consists of a single chain glycoprotein and is 839 amino acids long. It is comprised of a 320 residue N-terminal exoplasmic domain that contains the LDL-binding site and consists of disulfide-bonded cysteine residues, a C-terminal cytosolic domain which traps the LDL receptor in clathrin-coated pits, and a sequence of 22 hydrophobic amino acids within the plasma membrane in the form of an alpha helix. [5]


LDL particles bind to an LDL receptor on the plasma membrane, forming a receptor-ligand complex that is internalized in a clathrin-coated pit that pinches off to become a coated vesicle. After endocytosis, the LDL particle and its receptors are internalized by receptor-mediated endocytosis and degraded in the lysozyme. The clathrin coat depolymerizes, forming an early endosome which fuses with a late endosome where the low pH causes the LDL particles to dissociate from the LDL receptors. In the lysozyme, the apo-B protein of the LDL is degraded to amino acids, and cholesterol esters are hydrolyzed to fatty acids and cholesterol. [2]


Apolipoproteins serve a structural role in phospholipid membranes, acting as ligands for lipoprotein receptors, guiding the formation of lipoproteins, and serving as activators or inhibitors of enzymes involved in the metabolism of lipoproteins. Lipoproteins are critical for absorption and transport of dietary lipids by the small intestine and moving lipids from the liver to peripheral tissues and back from peripheral tissues to the liver and intestine. They are also crucial for the transport toxic foreign hydrophobic and amphipathic compounds, including bacterial endotoxin from areas of invasion and infection. [6]


The LDL receptor is on the liver and most other tissues. It recognizes Apo B 100 and Apo E, mediating the uptake of LDL, chylomicron remnants, and IDL, through endocytosis. After internalization, the lipoprotein particle is degraded in lysosomes and cholesterol is released. When cholesterol enters the cell, HMG CoA reductase activity increases, then synthesizes cholesterol and modulates the expression of LDL receptors. LDL receptors on the liver determine plasma LDL levels. When there is a low number or receptors, less LDL can be taken up from the blood by the liver, leading to high plasma LDL levels. Conversely, when there are more LDL receptors, more LDL is taken up from the blood by the liver, leading to low plasma LDL levels.

Levels of cholesterol regulate the number of LDL receptors in the cell. If the cell senses a decrease in cholesterol levels, the transcription factor SREBP is transported from the endoplasmic reticulum to Golgi where proteases cleave and activate SREBP which moves to the nucleus and increases expression of LDL receptors. When cholesterol levels are low in the cell, high SREBP remains in the endoplasmic reticulum in an inactive form, and expression of LDL receptors is decreased. [7]


In testing for hypercholesterolemia, a fasting lipid panel should be ordered, along with labs to rule out secondary causes.[8] In the fasting lipid panel, a total cholesterol of greater than 200 mg/dL and LDL cholesterol greater than 130 mg/dL is considered abnormal.[9] Secondary causes of hyperlipidemia should be ruled out through testing of fasting blood glucose, hemoglobin A1c, thyroid stimulating hormone, alkaline phosphatase, and urinalysis to assess for proteinuria.[10]


Hypercholesterolemia occurs due to excess cholesterol from diet, bile, or intestines. The liver releases triglycerides into the plasma in the form of VLDLS.[11] The intestines release triglycerides into the plasma in the form of chylomicrons. Once in the plasma, the VLDL is converted into LDL. LDL in the plasma then interacts with the LDL receptor on cells in various tissues.[12]

Clinical Significance

Increased LDL is associated with increased risk of cardiovascular disease.[13] It is commonly associated with diabetes, hypertension, hypertriglyceridemia, and atherosclerosis.[14] Through typically asymptomatic, hypercholesterolemia could present with metabolic syndrome, in which the patient would present with hypertension. In more severe hypercholesterolemia, patients may present with xanthomas with yellow nodules or plaques on the achilles tendon; for example, xanthelasma on the eyelids or corneal arcus with white rings lining the cornea.[15]